为您找到相关结果约500个

你是不是要搜索 期刊Luxturna(AAV) 遗传性视网膜疾病 点击跳转

Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy

Luxturna: FDA documents reveal the value of a costly gene therapy

Gene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease

AAV genome modification for efficient AAV production

Approved indication: inherited retinal dystrophy Luxturna (Novartis) vials containing concentrate for

Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors

T Cell-Mediated Immune Responses to AAV and AAV Vectors

Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions

Chem-AAV: Chemically Modified AAV for Gene Therapy

Chem-AAV: Chemically Modified AAV for Targeting Gene Delivery

An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor

Opinion of DOG, RG and BVA on the therapeutic Use of Voretigene Neparvovec (Luxturna (R)) in Ophthalmology

Successful Transduction with AAV Vectors after Selective Depletion of Anti-AAV Antibodies by Immunoadsorption

Intrathymic AAV gene delivery

AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than MV-1 and AAV-6

为您找到相关结果约500个

共500条页码: 1/34页15条/页